InnoPharmax Inc. (TPEX:4172)
Taiwan
· Delayed Price · Currency is TWD 14.65
-0.20 (-1.35%)
Apr 29, 2026, 1:53 PM CST
InnoPharmax Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 68.99 | 32.3 | 46.07 | 29.13 | 48.06 | Upgrade
|
| Revenue Growth (YoY) | 113.60% | -29.90% | 58.15% | -39.38% | -64.89% | Upgrade
|
| Cost of Revenue | 59.16 | 11.53 | 28.62 | 29.51 | 40.65 | Upgrade
|
| Gross Profit | 9.83 | 20.76 | 17.46 | -0.38 | 7.41 | Upgrade
|
| Selling, General & Admin | 26.36 | 21.43 | 22.97 | 21.51 | 22.43 | Upgrade
|
| Research & Development | 155.24 | 89.22 | 59.33 | 71.94 | 60.2 | Upgrade
|
| Operating Expenses | 181.59 | 116.74 | 82.3 | 92.95 | 81.79 | Upgrade
|
| Operating Income | -171.76 | -95.98 | -64.84 | -93.33 | -74.37 | Upgrade
|
| Interest Expense | -0.38 | -0.31 | -0.37 | -0.26 | -0.4 | Upgrade
|
| Interest & Investment Income | 2.84 | 1.92 | 1.64 | 0.98 | 1.01 | Upgrade
|
| Earnings From Equity Investments | -10.24 | -8.12 | -9.3 | -5.82 | -15.32 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.94 | 0.4 | -0.07 | -0.13 | -0.79 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.33 | 5.12 | 3.5 | -4.6 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | -180.82 | -96.97 | -69.43 | -103.15 | -89.81 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.03 | - | Upgrade
|
| Asset Writedown | -0.08 | - | -1.4 | - | -3.16 | Upgrade
|
| Pretax Income | -180.89 | -96.97 | -70.83 | -103.18 | -92.97 | Upgrade
|
| Income Tax Expense | 3.51 | 2.32 | - | - | - | Upgrade
|
| Net Income | -184.4 | -99.29 | -70.83 | -103.18 | -92.97 | Upgrade
|
| Net Income to Common | -184.4 | -99.29 | -70.83 | -103.18 | -92.97 | Upgrade
|
| Shares Outstanding (Basic) | 108 | 97 | 92 | 87 | 86 | Upgrade
|
| Shares Outstanding (Diluted) | 108 | 97 | 92 | 87 | 86 | Upgrade
|
| Shares Change (YoY) | 10.36% | 5.83% | 6.20% | 0.31% | 12.92% | Upgrade
|
| EPS (Basic) | -1.71 | -1.02 | -0.77 | -1.19 | -1.08 | Upgrade
|
| EPS (Diluted) | -1.71 | -1.02 | -0.77 | -1.19 | -1.08 | Upgrade
|
| Free Cash Flow | -134.47 | -76.75 | -48.97 | -100.08 | -51.48 | Upgrade
|
| Free Cash Flow Per Share | -1.25 | -0.79 | -0.53 | -1.15 | -0.60 | Upgrade
|
| Gross Margin | 14.25% | 64.29% | 37.89% | -1.29% | 15.43% | Upgrade
|
| Operating Margin | -248.98% | -297.18% | -140.73% | -320.35% | -154.76% | Upgrade
|
| Profit Margin | -267.29% | -307.43% | -153.74% | -354.17% | -193.44% | Upgrade
|
| Free Cash Flow Margin | -194.92% | -237.64% | -106.29% | -343.51% | -107.11% | Upgrade
|
| EBITDA | -169.97 | -93.92 | -62.12 | -89.41 | -69.33 | Upgrade
|
| EBITDA Margin | -246.38% | -290.81% | -134.83% | - | -144.25% | Upgrade
|
| D&A For EBITDA | 1.79 | 2.06 | 2.72 | 3.92 | 5.05 | Upgrade
|
| EBIT | -171.76 | -95.98 | -64.84 | -93.33 | -74.37 | Upgrade
|
| EBIT Margin | -248.98% | -297.18% | -140.73% | - | -154.76% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.